

Ultragenyx Pharmaceutical Inc.  
Form 8-K  
June 08, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 4, 2018**

**ULTRAGENYX PHARMACEUTICAL INC.**

**(Exact name of registrant as specified in charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**001-36276**  
**(Commission**  
**File Number)**

**27-2546083**  
**(IRS Employer**  
**Identification No.)**

**60 Leveroni Court, Novato, California**

**94949**

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (415) 483-8800

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 4, 2018, Jayson Dallas, M.D. notified Ultragenyx Pharmaceutical Inc. (the *Company* ) of his decision to resign from his position as Chief Commercial Officer and Executive Vice President of the Company, effective as of June 18, 2018. Dr. Dallas resigned to assume the chief executive officer position with a public biotech company.

\* \* \*

- 2 -

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 8, 2018

Ultragenyx Pharmaceutical Inc.

By: /s/ Shalini Sharp  
Shalini Sharp  
Executive Vice President, Chief Financial Officer